Lyon, 11 October 2018 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, announces today that Rodolphe Besserve, Head of the Start-Ups and French Techs (SuFT Advisory) activity at Société Générale, is joining its Board of Directors as independent director. Mr. Besserve is set to replace the representative of Sofimac Innovation, CEO François Miceli, who is resigning. His appointment will be subject to ratification at the next shareholders' meeting.
In 2005, Mr. Besserve joined Société Générale, where he helped to create and develop the biotech/medtech practice. As corporate finance expert, especially in the biotechnology field, he has concluded over 40 transactions in various forms over the past years. Mr. Besserve was a financial analyst in the healthcare sector at Kepler Equities and Bryan Garnier before joining the bank. He graduated from the École Supérieure de Chimie Physique Électronique de Lyon and the Emlyon Business School.
“I want to thank Sofimac Innovation, especially Cécile Thébault and François Miceli, who have been with us since 2014,” said Theranexus Chairman and CEO Franck Mouthon. “We are pleased to welcome Rodolphe Besserve to our Board of Directors. His experience in corporate finance and the listed biotech industry will be assets for the growth of Theranexus.”
“I wish to thank the Board of Directors for its trust,” said Mr. Besserve, new independent director at Theranexus. “I'm delighted to share my experience with Theranexus. The technology Theranexus uses, as well as its growth strategy, which are especially appealing in the healthcare industry, have a high potential to meet patients' needs and the pharmaceutical industry's expectations.”
|ABOUT THERANEXUS |
Theranexus is a clinical-stage biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA) in 2013. It develops drug candidates for the treatment of nervous system diseases. Theranexus identified the key role played by non-neuronal cells (also known as “glial cells”) in the body's response to psychotropic drugs (which target the neurons). The company is a pioneer in the design and development of drug candidates affecting the interaction between neurons and glial cells. The unique, patented technology used by Theranexus is designed to improve the efficacy of psychotropic drugs already approved and on the market, by combining them with a glial cell modulator. This strategy of combining its innovations with registered drugs means Theranexus can significantly reduce development time and costs and considerably increase the chance of its drugs reaching the market.
The proprietary, adaptable Theranexus platform can generate different proprietary drug candidates offering high added-value for multiple indications.
Theranexus is listed on the Euronext Growth market in Paris (FR0013286259- ALTHX).
More information at: www.theranexus.com
Financial and Administrative Director
ACTUS finance & communication
Caroline Lesage / Théo Martin
+33 (0)1 53 67 36 79 / +33 (0)1 53 67 36 75
+ 33 (0)6 07 76 82 83